Cargando…
The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia
Anagrelide (ANA) is a drug with specific platelet-lowering activity, used primarily in ET, registered as a second-line drug in essential thrombocythemia (ET) in Europe and in some countries as first-line therapy, in USA licensed by FDA for thrombocythemia in myeloproliferative neoplasms (MPN). The p...
Autor principal: | Birgegård, Gunnar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5031713/ https://www.ncbi.nlm.nih.gov/pubmed/27497846 http://dx.doi.org/10.1007/s11899-016-0335-0 |
Ejemplares similares
-
Ruxolitinib: Long-Term Management of Patients with Myelofibrosis and Future Directions in the Treatment of Myeloproliferative Neoplasms
por: Yacoub, A., et al.
Publicado: (2014) -
Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update
por: Bhatnagar, Neha, et al.
Publicado: (2016) -
Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019) -
Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration
por: Jain, Tania, et al.
Publicado: (2023) -
ASXL1 mutations accelerate bone marrow fibrosis via EGR1-TNFA axis-mediated neoplastic fibrocyte generation in myeloproliferative neoplasms
por: Shi, Zhongxun, et al.
Publicado: (2022)